Abstract
The Essure implant is a Food and Drug Administration (FDA) - approved form of hysteroscopic sterilization. The device has been available since 2002 with over half a million placed in the United States. The safety and efficacy profile has been demonstrated in the literature and supported by the FDA. Here, we present a rare case of bilateral perforation into the abdominal cavity with one device ultimately let in-situ. Although Bayer, the manufacturer of Essure, plans to stop sale of the product by December 31, 2018 for financial reasons, providers may continue to have questions and concerns from implants placed previously.
Highlights
The Essure implant is a Food and Drug Administration (FDA) - approved form of hysteroscopic sterilization
A 10 mm umbilical incision was made with two accessory 5 mm bilateral lower quadrant port sites
The right Essure implant was laying in the right adnexa with mild adhesions (Figure 1) and removed
Summary
The Essure implant is a Food and Drug Administration (FDA) - approved form of hysteroscopic sterilization. It did not appear to be embedded or constricting the lumen. Her salpingectomy was completed without any complications.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
